EPS for PTC Therapeutics, Inc. (PTCT) Expected At $-0.23

February 20, 2018 - By Adrian Mccoy

 EPS for PTC Therapeutics, Inc. (PTCT) Expected At $ 0.23
Investors sentiment increased to 1.71 in 2017 Q3. Its up 0.79, from 0.92 in 2017Q2. It increased, as 13 investors sold PTC Therapeutics, Inc. shares while 28 reduced holdings. 25 funds opened positions while 45 raised stakes. 32.89 million shares or 5.85% more from 31.07 million shares in 2017Q2 were reported.
Hanseatic Mngmt Svcs invested in 105 shares. Parametric Port Ltd Liability Com has 0% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 26,739 shares. Connor Clark Lunn Invest Management has 0.05% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT). Rhumbline Advisers reported 42,103 shares or 0% of all its holdings. 383,134 were accumulated by Bank & Trust Of America Corporation De. Metropolitan Life Ins invested in 27,393 shares or 0% of the stock. Retail Bank Of Mellon Corp invested in 0% or 171,477 shares. Moreover, Matarin Capital Mgmt Ltd Liability Corporation has 0.32% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 187,073 shares. 65,565 were accumulated by Swiss Bank. New York-based Consonance Cap Management Ltd Partnership has invested 8.73% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Virginia Retirement Et Al accumulated 18,700 shares or 0% of the stock. Employees Retirement Systems Of Ohio stated it has 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). 40,762 were accumulated by Alps Advsrs Incorporated. Axa invested in 0.01% or 133,400 shares. State Board Of Administration Of Florida Retirement Systems invested in 21,987 shares.

Since January 3, 2018, it had 0 buys, and 4 sales for $61,523 activity. Almstead Neil Gregory had sold 703 shares worth $12,675 on Friday, January 5. 2,230 PTC Therapeutics, Inc. (NASDAQ:PTCT) shares with value of $40,207 were sold by Peltz Stuart Walter.

Analysts expect PTC Therapeutics, Inc. (NASDAQ:PTCT) to report $-0.23 EPS on March, 15.They anticipate $0.55 EPS change or 70.51 % from last quarter’s $-0.78 EPS. After having $-0.67 EPS previously, PTC Therapeutics, Inc.’s analysts see -65.67 % EPS growth. The stock decreased 2.37% or $0.58 during the last trading session, reaching $23.93. About 581,392 shares traded. PTC Therapeutics, Inc. (NASDAQ:PTCT) has risen 104.51% since February 20, 2017 and is uptrending. It has outperformed by 87.81% the S&P500.

PTC Therapeutics, Inc. (NASDAQ:PTCT) Ratings Coverage

Among 12 analysts covering PTC Therapeutics (NASDAQ:PTCT), 4 have Buy rating, 1 Sell and 7 Hold. Therefore 33% are positive. PTC Therapeutics had 35 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) has “Neutral” rating given on Tuesday, February 23 by JP Morgan. Credit Suisse initiated the stock with “Outperform” rating in Wednesday, January 20 report. As per Thursday, November 16, the company rating was upgraded by J.P. Morgan. RBC Capital Markets maintained the stock with “Outperform” rating in Friday, October 16 report. RBC Capital Markets maintained the stock with “Sector Perform” rating in Friday, November 11 report. The firm earned “Buy” rating on Friday, November 11 by Citigroup. The firm earned “Hold” rating on Wednesday, February 24 by Jefferies. RBC Capital Markets maintained it with “Hold” rating and $15.0 target in Thursday, September 14 report. The firm has “Hold” rating by Jefferies given on Friday, October 23. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) has “Hold” rating given on Wednesday, July 5 by RBC Capital Markets.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company has market cap of $992.85 million. The company's lead product is Translarna , for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and which is in phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. It currently has negative earnings. It also develops Translarna, which is in Phase II clinical trials for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, nonsense mutation aniridia, and nonsense mutation Dravet syndrome/CDKL5; and RG7916 that is in Phase I clinical trials to treat spinal muscular atrophy.

More recent PTC Therapeutics, Inc. (NASDAQ:PTCT) news were published by: Prnewswire.com which released: “PTC Therapeutics Launches Fourth Annual STRIVE Grant Award Program for …” on February 13, 2018. Also Prnewswire.com published the news titled: “PTC Therapeutics to Present at the RBC Capital Markets Global Healthcare …” on February 09, 2018. Streetinsider.com‘s news article titled: “Form 8-K PTC THERAPEUTICS, INC. For: Jan 27” with publication date: January 29, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.